MAZE THERAPEUTICS INC (MAZE) Fundamental Analysis & Valuation

NASDAQ:MAZE • US5787841007

Current stock price

28.09 USD
-0.91 (-3.14%)
Last:

This MAZE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. MAZE Profitability Analysis

1.1 Basic Checks

  • In the past year MAZE has reported negative net income.
  • MAZE had a negative operating cash flow in the past year.
MAZE Yearly Net Income VS EBIT VS OCF VS FCFMAZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.81%, MAZE belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
  • MAZE has a better Return On Equity (0.90%) than 80.73% of its industry peers.
  • MAZE has a better Return On Invested Capital (11.37%) than 90.63% of its industry peers.
Industry RankSector Rank
ROA 0.81%
ROE 0.9%
ROIC 11.37%
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAZE Yearly ROA, ROE, ROICMAZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • MAZE's Profit Margin of 2.03% is amongst the best of the industry. MAZE outperforms 80.21% of its industry peers.
  • MAZE has a Operating Margin of 34.38%. This is amongst the best in the industry. MAZE outperforms 95.83% of its industry peers.
Industry RankSector Rank
OM 34.38%
PM (TTM) 2.03%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MAZE Yearly Profit, Operating, Gross MarginsMAZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. MAZE Health Analysis

2.1 Basic Checks

  • MAZE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • MAZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MAZE Yearly Shares OutstandingMAZE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
MAZE Yearly Total Debt VS Total AssetsMAZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • MAZE has an Altman-Z score of 20.03. This indicates that MAZE is financially healthy and has little risk of bankruptcy at the moment.
  • MAZE has a better Altman-Z score (20.03) than 90.63% of its industry peers.
  • MAZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.03
ROIC/WACC1.23
WACC9.24%
MAZE Yearly LT Debt VS Equity VS FCFMAZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • MAZE has a Current Ratio of 17.70. This indicates that MAZE is financially healthy and has no problem in meeting its short term obligations.
  • MAZE's Current ratio of 17.70 is amongst the best of the industry. MAZE outperforms 90.63% of its industry peers.
  • A Quick Ratio of 17.70 indicates that MAZE has no problem at all paying its short term obligations.
  • The Quick ratio of MAZE (17.70) is better than 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 17.7
Quick Ratio 17.7
MAZE Yearly Current Assets VS Current LiabilitesMAZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MAZE Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 8.55% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.88%
EPS Next 2Y-3.71%
EPS Next 3Y5.97%
EPS Next 5Y8.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAZE Yearly Revenue VS EstimatesMAZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
MAZE Yearly EPS VS EstimatesMAZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. MAZE Valuation Analysis

4.1 Price/Earnings Ratio

  • MAZE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MAZE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAZE Price Earnings VS Forward Price EarningsMAZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MAZE is valued cheaper than 82.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.69
MAZE Per share dataMAZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.71%
EPS Next 3Y5.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MAZE Dividend Analysis

5.1 Amount

  • MAZE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MAZE Fundamentals: All Metrics, Ratios and Statistics

MAZE THERAPEUTICS INC

NASDAQ:MAZE (4/7/2026, 2:50:41 PM)

28.09

-0.91 (-3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25
Earnings (Next)N/A
Inst Owners88.17%
Inst Owner Change0%
Ins Owners1.88%
Ins Owner Change-32.11%
Market Cap1.35B
Revenue(TTM)N/A
Net Income(TTM)3.40M
Analysts86.67
Price Target61.71 (119.69%)
Short Float %8.54%
Short Ratio4.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.25%
Min EPS beat(2)8.68%
Max EPS beat(2)11.81%
EPS beat(4)2
Avg EPS beat(4)-1030.11%
Min EPS beat(4)-4091.29%
Max EPS beat(4)11.81%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.51%
PT rev (3m)39.88%
EPS NQ rev (1m)-1.08%
EPS NQ rev (3m)-2.11%
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.07
P/FCF N/A
P/OCF N/A
P/B 3.56
P/tB 3.56
EV/EBITDA 15.69
EPS(TTM)-3.23
EYN/A
EPS(NY)-3.2
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS3.48
BVpS7.89
TBVpS7.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.81%
ROE 0.9%
ROCE 14.4%
ROIC 11.37%
ROICexc 284.14%
ROICexgc 284.14%
OM 34.38%
PM (TTM) 2.03%
GM N/A
FCFM N/A
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 52.32%
Cap/Sales 0.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.7
Quick Ratio 17.7
Altman-Z 20.03
F-Score6
WACC9.24%
ROIC/WACC1.23
Cap/Depr(3y)32.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.45%
EPS Next Y0.88%
EPS Next 2Y-3.71%
EPS Next 3Y5.97%
EPS Next 5Y8.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y158.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-660.53%
EBIT Next 3Y-105.62%
EBIT Next 5YN/A
FCF growth 1Y185.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y187.48%
OCF growth 3YN/A
OCF growth 5YN/A

MAZE THERAPEUTICS INC / MAZE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MAZE THERAPEUTICS INC (MAZE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MAZE.


What is the valuation status of MAZE THERAPEUTICS INC (MAZE) stock?

ChartMill assigns a valuation rating of 1 / 10 to MAZE THERAPEUTICS INC (MAZE). This can be considered as Overvalued.


What is the profitability of MAZE stock?

MAZE THERAPEUTICS INC (MAZE) has a profitability rating of 4 / 10.


What is the financial health of MAZE THERAPEUTICS INC (MAZE) stock?

The financial health rating of MAZE THERAPEUTICS INC (MAZE) is 9 / 10.